Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

This study has been completed.

Sponsor:

Collaborator:

Embil Pharmaceutical Co. Ltd

Information provided by (Responsible Party):

Jane Schwebke, University of Alabama at Birmingham

ClinicalTrials.gov Identifier:

NCT01361048

First received: May 24, 2011

Last updated: February 22, 2017

Last verified: February 2017

History of Changes

Purpose

The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.

Condition	Intervention	Phase
Trichomonas Vaginitis	Drug: oral metronidazole Drug: neo penotran forte Drug: neo penotran forte once a day	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

Resource links provided by NLM:

MedlinePlus related topics: Trichomoniasis

Drug Information available for: Metronidazole

U.S. FDA Resources

Further study details as provided by Jane Schwebke, University of Alabama at Birmingham:

Primary Outcome Measures:

Percentage of Participants Cured of Vaginal Trichmonas [ Time Frame: day 12-15 ]
percentage of participants achieving microbiological cure of trichomonas

Secondary Outcome Measures:

Tolerability of the Study Product [ Time Frame: day 12-15 day 30-35 ]
any side effects?


Enrollment:	40
Study Start Date:	December 2011
Study Completion Date:	January 2013
Primary Completion Date:	August 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: oral metronidazole control arm	Drug: oral metronidazole 2 gm oral once
Experimental: neo penotran forte neo penotran forte vaginal suppository twice a day for 7 days	Drug: neo penotran forte neo penotran forte intravaginal twice a day for 7 days
Experimental: neo penotran forte once a day neo penotran forte vaginal suppository once a day for 7 days	Drug: neo penotran forte once a day neo penotran forte intravaginally once a day for 7 days

Eligibility


Ages Eligible for Study:	19 Years and older (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

presence of trichomonas

Exclusion Criteria:

pregnant or nursing
known immunodeficiency
allergy to study drugs
concurrent yeast infection
history of seizures or peripheral neuropathy
unwillingness to abstain from alcohol during treatment period and for 48 hrs after concurrent lithium
anticoagulation therapy, and abuse
patient expected to have menses within 8 days of enrollment

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01361048

Locations


United States, Alabama
Personal Health Clinic UAB
Birmingham, Alabama, United States, 35294

Sponsors and Collaborators

University of Alabama at Birmingham

Embil Pharmaceutical Co. Ltd

More Information


Responsible Party:	Jane Schwebke, Professor of Medicine, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:	NCT01361048 History of Changes
Other Study ID Numbers:	TV-01
Study First Received:	May 24, 2011
Results First Received:	November 18, 2013
Last Updated:	February 22, 2017

Keywords provided by Jane Schwebke, University of Alabama at Birmingham:


trichomonas

Additional relevant MeSH terms:


Trichomonas Infections Vaginitis Trichomonas Vaginitis Protozoan Infections Parasitic Diseases Vaginal Diseases	Genital Diseases, Female Metronidazole Anti-Infective Agents Antiprotozoal Agents Antiparasitic Agents

ClinicalTrials.gov processed this record on June 26, 2017

To Top